272 related articles for article (PubMed ID: 29556695)
1. Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.
Kim DW; Saussele S; Williams LA; Mohamed H; Rong Y; Zyczynski T; Pinilla-Ibarz J; Abruzzese E
Ann Hematol; 2018 Aug; 97(8):1357-1367. PubMed ID: 29556695
[TBL] [Abstract][Full Text] [Related]
2. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
Shah NP; Rousselot P; Schiffer C; Rea D; Cortes JE; Milone J; Mohamed H; Healey D; Kantarjian H; Hochhaus A; Saglio G
Am J Hematol; 2016 Sep; 91(9):869-74. PubMed ID: 27192969
[TBL] [Abstract][Full Text] [Related]
4. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
Murai K; Akagi T; Shimosegawa K; Sugawara T; Ishizawa K; Ito S; Murai K; Motegi M; Yokoyama H; Noji H; Tajima K; Kimura J; Chou T; Ogawa K; Harigae H; Kubo K; Oba K; Sakamoto J; Ishida Y
Eur J Haematol; 2015 Dec; 95(6):558-65. PubMed ID: 25703064
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.
Cortes JE; Lipton JH; Miller CB; Busque L; Akard LP; Pinilla-Ibarz J; Keir C; Warsi G; Lin FP; Mauro MJ
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):286-96. PubMed ID: 26993758
[TBL] [Abstract][Full Text] [Related]
6. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.
Cortes JE; Saglio G; Kantarjian HM; Baccarani M; Mayer J; Boqué C; Shah NP; Chuah C; Casanova L; Bradley-Garelik B; Manos G; Hochhaus A
J Clin Oncol; 2016 Jul; 34(20):2333-40. PubMed ID: 27217448
[TBL] [Abstract][Full Text] [Related]
7. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Ota S; Matsukawa T; Yamamoto S; Ito S; Shindo M; Sato K; Kondo T; Kohda K; Sakai H; Mori A; Takahashi T; Ikeda H; Kuroda H; Haseyama Y; Yamamoto M; Sarashina T; Yoshida M; Kobayashi R; Nishio M; Ishihara T; Hirayama Y; Kakinoki Y; Kobayashi H; Fukuhara T; Imamura M; Kurosawa M
Eur J Haematol; 2018 Jul; 101(1):95-105. PubMed ID: 29660177
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study.
Cortes JE; Jiang Q; Wang J; Weng J; Zhu H; Liu X; Hochhaus A; Kim DW; Radich J; Savona M; Martin-Regueira P; Sy O; Gurnani R; Saglio G
Leukemia; 2020 Aug; 34(8):2064-2073. PubMed ID: 32265500
[TBL] [Abstract][Full Text] [Related]
9. Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.
Scalzulli E; Caocci G; Efficace F; Rizzo L; Colafigli G; Di Prima A; Pepe S; Fegatelli DA; Carmosino I; Diverio D; Latagliata R; La Nasa G; Martelli M; Foà R; Breccia M
Ann Hematol; 2021 May; 100(5):1213-1219. PubMed ID: 33677654
[TBL] [Abstract][Full Text] [Related]
10. Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors.
Okamoto S; Ureshino H; Kawaguchi A; Miyazono M; Ikeda Y; Kimura S
Int J Hematol; 2020 Jul; 112(1):41-45. PubMed ID: 32306183
[TBL] [Abstract][Full Text] [Related]
11. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis.
Tang L; Zhang H; Peng YZ; Li CG; Jiang HW; Xu M; Mei H; Hu Y
BMC Cancer; 2019 Aug; 19(1):849. PubMed ID: 31462241
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
Hehlmann R; Cortes JE; Zyczynski T; Gambacorti-Passerini C; Goldberg SL; Mauro MJ; Michallet M; Simonsson B; Williams LA; Gajavelli S; DeGutis I; Sen GP; Paquette RL
Am J Hematol; 2019 Jan; 94(1):46-54. PubMed ID: 30290003
[TBL] [Abstract][Full Text] [Related]
15. Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients.
Murai K; Yamaguchi K; Ito S; Miyagishima T; Shindo M; Wakasa K; Inomata M; Nagashima T; Kondo T; Fujimoto N; Yamamoto S; Yonezumi M; Oyake T; Kowata S; Tsukushi Y; Mine T; Meguro K; Ikeda K; Watanabe R; Saito S; Sato S; Tajima K; Chou T; Kubo K; Oba K; Sakamoto J; Ishida Y;
Eur J Haematol; 2018 Jan; 100(1):27-35. PubMed ID: 28895203
[TBL] [Abstract][Full Text] [Related]
16. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis.
Sasaki K; Kantarjian H; Jabbour E; Ravandi F; Takahashi K; Konopleva M; Borthakur G; Garcia-Manero G; Wierda W; Daver N; Jain P; Satta T; Pierce S; Rios MB; Cortes JE
Haematologica; 2016 Aug; 101(8):e324-7. PubMed ID: 27175025
[No Abstract] [Full Text] [Related]
17. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.
Sasaki K; Kantarjian HM; Jain P; Jabbour EJ; Ravandi F; Konopleva M; Borthakur G; Takahashi K; Pemmaraju N; Daver N; Pierce SA; O'Brien SM; Cortes JE
Cancer; 2016 Jan; 122(2):238-48. PubMed ID: 26479889
[TBL] [Abstract][Full Text] [Related]
18. Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia.
Bostan H; Toptas T; Tanrikulu FP; Kut K; Arikan F; Yilmaz F; Atagunduz I; Firatli-Tuglular T
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):836-842. PubMed ID: 32958432
[TBL] [Abstract][Full Text] [Related]
19. Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase.
Yu L; Liu J; Huang X; Jiang Q
Sci Rep; 2019 Nov; 9(1):17601. PubMed ID: 31772301
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice.
Zackova D; Klamova H; Belohlavkova P; Stejskal L; Necasova T; Semerad L; Weinbergerova B; Srbova D; Voglova J; Cicatkova P; Sustkova Z; Hornak T; Baranova J; Prochazkova J; Mayer J
Leuk Lymphoma; 2021 Jan; 62(1):194-202. PubMed ID: 33021423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
